Table 12.

Short version: statements pertaining to gastric adenocarcinoma and proximal polyposis of the stomach

Statements	Level of evidence and agreement
GAPPS.1: Genetic testing should be offered to individuals with a clinical suspicion of GAPPS.	LE: Strong Agreement: 95% (SA 52%; A 43%; N 5%)
GAPPS.2A: The age to start upper GI surveillance in asymptomatic individuals at risk of gastric cancer should be evaluated on a case-by-case basis. The youngest age of gastric cancer in the family should be considered.	LE: Low Agreement: 82% (SA 25%; A 57%; N 11%; D 7%)
GAPPS.2B: Surveillance endoscopic intervals for GAPPS families should be flexible and decided on a case-by-case basis.	LE: Low Agreement: 93% (SA 24%; A 69%; N 3%; D 4%)
GAPPS.3: In GAPPS patients CRC surveillance may be considered, particularly when there is a family history of CRC.	LE: Low Agreement: 85% (SA 37%; A 48%; N 7%; D 8%)
GAPPS.4A: GAPPS results in a high risk of gastric cancer. Total gastrectomy should be considered in cases of high-grade dysplasia and progressive gastric polyposis.	LE: Low Agreement: 96% (SA 52%; A 44%; N 4%)
GAPPS.4B: There is not enough evidence to recommend an age for risk-reducing prophylactic gastrectomy: the decision should be individualized.	LE: Low Agreement: 96% (SA 52%; A 44%; N 4%)

A, agree; CRC, colorectal cancer; D, disagree; GAPPS, gastric adenocarcinoma and proximal polyposis of the stomach; GI, gastrointestinal; LE, level of evidence; N, neutral; SA, strongly agree; SD, strongly disagree.